Research Topics
Species | SIMON ALEXANDER MALLALSummaryAffiliation: Murdoch University Country: Australia Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Unique features of HLA-mediated HIV evolution in a Mexican cohort: a comparative studySantiago Avila-Ríos
Center for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City, Mexico
Retrovirology 6:72. 2009..However, it is not known whether characteristic HLA frequency distributions in different populations have resulted in additional unique footprints...
HLA-B*5701 screening for hypersensitivity to abacavirSimon Mallal
Royal Perth Hospital and Murdoch University, Perth, Australia
N Engl J Med 358:568-79. 2008..This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir...
Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort studyA Rauch
Centre for Clinical Immunology and Biomedical Statistics, Perth, Australia
Clin Infect Dis 43:99-102. 2006..7% of whom were positive for HLA-B*5701), we confirm the usefulness of genetic risk stratification, with no cases of abacavir hypersensitivity among 148 HLA-B*5701-negative recipients...- HLA-B*5701 screening for susceptibility to abacavir hypersensitivityAndrew Lucas
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Level 2, North Block, Wellington Street, Perth, WA 6000, Australia
J Antimicrob Chemother 59:591-3. 2007..It also presents the screening's impact on clinical practice and discusses the practical considerations that influence the introduction and cost-effectiveness of such screening... - Successful translation of pharmacogenetics into the clinic: the abacavir exampleElizabeth Phillips
Institute for Immunology and Infectious Diseases, Murdoch University and Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, Perth, Western Australia, Australia
Mol Diagn Ther 13:1-9. 2009..The abacavir 'example' can be applied to other drugs to facilitate the development and operationalization of genetic tests that may be useful to predict and prevent otherwise unpredictable drug reactions... - Cytokine profiling in abacavir hypersensitivity patientsCoral Ann M Almeida
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Australia
Antivir Ther 13:281-8. 2008..We have analysed the cytokine profile in antigen-presenting cells and the T-lymphocytes that are involved in the pathological immune response to abacavir... - A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndromeAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
Pharmacogenet Genomics 16:353-7. 2006..Following risk stratification with this assay, it would be anticipated that identification of HLA-B*5701 using molecular HLA typing methods would be required in <10% of the screened population... - Drug hypersensitivity in HIVElizabeth Phillips
Centre for Pharmacology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
Curr Opin Allergy Clin Immunol 7:324-30. 2007..This review focuses on the current knowledge of the epidemiology, pathophysiology and clinical features of drug hypersensitivity reactions of drugs used in the management of the HIV-infected patient... - Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variantAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Murdoch University, Second Floor, North Block, Royal Perth Hospital, Perth 6000, Australia
Proc Natl Acad Sci U S A 101:4180-5. 2004..These data indicate that the concurrence of HLA-B*5701 and Hsp70-Hom M493T alleles is necessary for the development of abacavir hypersensitivity, which is likely to be mediated by an HLA-B*5701-restricted immune response to abacavir... - External quality assessment of HLA-B*5701 reporting: an international multicentre surveyEmma Hammond
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
Antivir Ther 12:1027-32. 2007..We tested the proficiency of HLA-B*5701 typing among laboratories using sequence-specific primer PCR... - HIV/AIDS. HIV: experiencing the pressures of modern lifeDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
Science 307:1422-4. 2005 - Immune responses to abacavir in antigen-presenting cells from hypersensitive patientsAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia 6000, Australia
AIDS 21:1233-44. 2007..HLA-B*5701 and Hsp70 493T alleles have been shown to predict susceptibility to this hypersensitivity... - Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back againAnnalise Martin
Royal Perth Hospital and Murdoch University, Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Perth, 6000 Western Australia
Pharmacogenomics 7:15-23. 2006..This review also explores the broader implications of these findings... - Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifsMina John
Centre for Clinical Immunology and Biomedical Statistics, Institute for Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia
J Immunol 184:4368-77. 2010..This suggests that the interactions between the HLA/HIV peptide complex and the TCR vary significantly within HLA supertype groups, which, in turn, influences HIV-1 evolution... - Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell countsAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
AIDS 19:97-9. 2005..These data suggest that HLA-DRB1*0101 and the CD4 status may determine susceptibility to nevirapine hypersensitivity, consistent with a CD4 T-cell-dependent immune response to nevirapine-specific antigens... - Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitorsAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Murdoch University, Perth, Western Australia, Australia
Am J Hum Genet 72:549-60. 2003..These data indicate that NRTI therapy provides conditions permissive for the development of peripheral-blood mtDNA mutations in vivo... - Thymidine analogue-sparing highly active antiretroviral therapy (HAART)David Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
J HIV Ther 8:2-6. 2003..The safety and efficacy of TNF and ABC are also reviewed here, although the available data provide only limited knowledge of the long-term effects of these drugs in terms of toxicity and antiviral durability... - The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndromeDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital, Wellington Street, Perth, 6000, Western Australia
J HIV Ther 9:34-40. 2004..Implications for clinical assessment and management are also considered, within a broader contest that incorporates treatment efficacy as well as toxicity... - Associations between KIR epitope combinations expressed by HLA-B/-C haplotypes found in an HIV-1 infected study population may influence NK mediated immune responsesSilvana Gaudieri
Centre for Clinical Immunology and Biomedical Statistics, Murdoch University and Royal Perth Hospital, Perth, WA, Australia
Mol Immunol 42:557-60. 2005.... - Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapySilvana Gaudieri
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
Hepatology 49:1069-82. 2009.... - Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanismsDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
Antivir Ther 9:849-63. 2004..In this review, the clinical manifestations, risk factors and pathological basis for NRTI-associated toxicity syndromes are explored, with an emphasis on clinical assessment and management... - Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistanceMonika Tschochner
Institute for Immunology and Infectious Diseases, Royal Perth Hospital and Murdoch University, Perth, Australia
Antivir Ther 14:953-64. 2009..We examined naturally occurring polymorphisms in HIV-1 integrase sequences from 342 antiretroviral-naive individuals from the Western Australian HIV Cohort Study and the Swiss HIV Cohort Study... - Host genetics and viral infections: immunology taught by viruses, virology taught by the immune systemDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Level 2, North Block, Perth, Western Australia
Curr Opin Immunol 18:413-21. 2006..These issues can be considered within an evolutionary perspective that acknowledges the crucial role of adaptive host-viral relationships in shaping both host and pathogen genetic diversity... - Hyperlactatemia syndromes in people with HIV infectionMina John
Centre for Clinical Immunology, North Block Level 2, Royal Perth Hospital, Wellington Street, Perth, WA 6000, Australia
Curr Opin Infect Dis 15:23-9. 2002.... - Antiretroviral-therapy-associated lipoatrophy: current status and future directionsDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Australia
Sex Health 2:153-63. 2005.... - Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicityAnnalise M Martin
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Perth, Western Australia
Pharmacogenomics 5:643-55. 2004..g., major histocompatibility complex alleles associated with abacavir hypersensitivity). The current and potential clinical utility of pharmacogenetic testing in HIV management will also be emphasized... - Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapyDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, Royal Perth Hospital and Murdoch University, Western Australia, Australia
AIDS 17:1329-38. 2003..Morphologic assessment also supports a role for NRTI therapy in inducing adipocyte metabolic dysfunction and cell death... - Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance studyEmma L Hammond
Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Royal Perth Hospital and Murdoch University, Australia
J Clin Virol 27:97-110. 2003..CONCLUSION: All assays demonstrated good precision. The use of common standards is an important step in improving the comparability of data between laboratories... - Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophyDavid Nolan
Centre for Clinical Immunology and Biomedical Statistics, and Department of Clinical Immunology and Biochemical Genetics, Royal Perth Hospital, Perth, Western Australia
AIDS 17:121-3. 2003 - Exploiting knowledge of immune selection in HIV-1 to detect HIV-specific CD8 T-cell responsesCoral Ann M Almeida
Centre for Clinical Immunology and Biomedical Statistics, Institute of Immunology and Infectious Diseases, Murdoch University, Perth, Western Australia, Australia
Vaccine 28:6052-7. 2010..Sites of immune selection can reveal more immunogenic epitopes in HLA-diverse populations and offer insights into the nature of HLA-epitope targeting, which could be applied in vaccine design... - Adverse effects of antiretroviral therapy for HIV infection: a review of selected topicsDavid Nolan
Royal Perth Hospital and Murdoch University, Centre for Clinical Immunology and Biomedical Statistics, 2nd Floor, North Block, Wellington Street, Perth, 6000, Western Australia, Australia
Expert Opin Drug Saf 4:201-18. 2005..In this review, current and emerging drug toxicities are considered with an emphasis on lipodystrophy complications...
Research Grants
- HIV-1 adaptation to HLA-restricted immune responsesSimon Mallal; Fiscal Year: 2007..The results will be used to determine how well the immune responses induced by a given vaccine would recognise diverse, variably HLA-adapted HIV-1 strains at those epitopes most critical for the prevalent HLA types of the study cohort. ..